| REVENUE FROM CONTINUING OPERATIONS |
|
|
|
|
|
|
|
|
|
|
| South Africa^ |
7 376,8 |
|
35 |
|
6 159,9 |
|
38 |
|
20% |
|
| Asia Pacific |
7 590,5 |
|
37 |
|
6 021,0 |
|
37 |
|
26% |
|
| International @ |
3 726,1 |
|
18 |
|
2 522,9 |
|
15 |
|
48% |
|
| Sub-Saharan Africa |
2 081,5 |
|
10 |
|
1 651,7 |
|
10 |
|
26% |
|
| Total gross revenue |
20 774,9 |
|
100 |
|
16 355,5 |
|
100 |
|
27% |
|
| Adjustment* |
(1 466,9) |
|
|
|
(1 099,7) |
|
|
|
|
|
| Total revenue |
19 308,0 |
|
|
|
15 255,8 |
|
|
|
|
|
| OPERATING PROFIT BEFORE AMORTISATION FROM CONTINUING OPERATIONS |
|
|
|
|
|
|
|
|
|
|
| Adjusted for specific non-trading items ("EBITA") |
|
|
|
|
|
|
|
|
|
|
| South Africa |
1 965,3 |
|
35 |
|
1 768,4 |
|
40 |
|
11% |
|
| Operating profit# |
1 867,5 |
|
|
|
1 616,2 |
|
|
|
16% |
|
| Amortisation of intangible assets |
60,5 |
|
|
|
66,8 |
|
|
|
|
|
| Transaction costs |
31,3 |
|
|
|
— |
|
|
|
|
|
| Restructuring costs |
— |
|
|
|
3,4 |
|
|
|
|
|
| Impairment of assets |
6,0 |
|
|
|
82,0 |
|
|
|
|
|
| Asia Pacific |
1 894,0 |
|
34 |
|
1 460,2 |
|
33 |
|
30% |
|
| Operating profit# |
1 608,2 |
|
|
|
1 291,6 |
|
|
|
25% |
|
| Amortisation of intangible assets |
128,0 |
|
|
|
100,2 |
|
|
|
|
|
| Transaction costs |
6,0 |
|
|
|
— |
|
|
|
|
|
| Restructuring costs |
151,8 |
|
|
|
68,4 |
|
|
|
|
|
| International |
1 488,7 |
|
27 |
|
938,5 |
|
21 |
|
59% |
|
| Operating profit# |
1 321,7 |
|
|
|
790,9 |
|
|
|
67% |
|
| Amortisation of intangible assets |
60,8 |
|
|
|
41,1 |
|
|
|
|
|
| Settlement of product litigation |
43,0 |
|
|
|
— |
|
|
|
|
|
| Impairment of assets |
63,2 |
|
|
|
106,5 |
|
|
|
|
|
| Sub-Saharan Africa |
252,3 |
|
4 |
|
247,9 |
|
6 |
|
2% |
|
| Operating profit# |
245,9 |
|
|
|
241,9 |
|
|
|
2% |
|
| Amortisation of intangible assets |
6,4 |
|
|
|
4,2 |
|
|
|
|
|
| Restructuring costs |
— |
|
|
|
1,7 |
|
|
|
|
|
| Impairment of assets |
— |
|
|
|
0,1 |
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
| Total EBITA |
5 600,3 |
|
100 |
|
4 415,0 |
|
100 |
|
27% |
|
| ENTITY WIDE DISCLOSURE – REVENUE FROM CONTINUING OPERATIONS |
|
|
|
|
|
|
|
|
|
|
| Analysis of revenue in accordance with customer geography |
|
|
|
|
|
|
|
|
|
|
| South Africa – pharmaceutical |
6 201,9 |
|
30 |
|
5 161,7 |
|
32 |
|
20% |
|
| South Africa – consumer |
1 175,0 |
|
6 |
|
998,2 |
|
6 |
|
18% |
|
| Asia Pacific |
7 697,6 |
|
37 |
|
6 088,8 |
|
37 |
|
26% |
|
| Sub-Saharan Africa |
2 123,7 |
|
10 |
|
1 651,7 |
|
10 |
|
29% |
|
| Latin America |
1 567,3 |
|
7 |
|
1 023,7 |
|
6 |
|
53% |
|
| Rest of the world |
2 009,5 |
|
10 |
|
1 431,4 |
|
9 |
|
40% |
|
| Total gross revenue |
20 774,9 |
|
100 |
|
16 355,5 |
|
100 |
|
27% |
|
| Adjustment* |
(1 466,9) |
|
|
|
(1 099,7) |
|
|
|
|
|
| Total revenue |
19 308,0 |
|
|
|
15 255,8 |
|
|
|
27% |
|
| ^ |
Excludes intersegment revenue of R43,0 million (2012: R29,6 million). |
| @ |
Excludes intersegment revenue of R1 201,5 million (2012: R432,3 million). |
| * |
The profit share from the Aspen GSK Healthcare for Africa collaboration has been disclosed as revenue in the statement of comprehensive
income. For segmental purposes the total revenue for the Aspen GSK Healthcare for Africa collaboration has been included to provide
enhanced revenue visibility in this territory. |
| # |
The aggregate segmental operating profit total of R5 043,3 million (2012: R3 940,6 million) agrees to the statement of comprehensive income. |
|
